Bioretec has previously published a couple of post-market studies following the European RemeOs CE mark approval. Conducted in Switzerland, at Bern University Hospital. These will be used for the US portfolio expansion, after all. These were published 5 months and 6 months ago. Hopefully, a sufficient number of patients has already been recruited for the US market.
First case: a 5-year-old child.
“”“”“”“”“”"
5 weeks: Excellent bone healing with no callus formation, indicating stable compression, soft tissue translucency resolved, degradation zones around the screws decreasing, no local complications observed
4 months: Patient completely symptom-free, pain-free normal mobility on both sides restored, Radiological confirmation of complete fracture consolidation
Outcome: Bone structure restored to normal with no clinical symptoms
“”“”“”“”"
#pediatricorthopedics #medicalinnovation #fracturerecovery #orthopedicsurgery #absorbableimplants | Bioretec Ltd. #pediatricorthopedics #medicalinnovation #fracturerecovery #orthopedicsurgery #absorbableimplants | Bioretec Ltd.
Second case: a 14-year-old adolescent.
“”“”“”“”“”“”
5 weeks: Cast removed — no local complications, pain-free, and early mobilization initiated
4 months: Complete fracture healing achieved — translucent zones in the bone and around the screws have nearly disappeared
Outcome: Bone structure restored to normal with no clinical symptoms
“”“”“”“”“”“”
#remeos #pediatricorthopedics #fracturefixations #upperextremity #traumasurgery | Bioretec Ltd. #remeos #pediatricorthopedics #fracturefixations #upperextremity #traumasurgery | Bioretec Ltd.